Loading company…
Baltimore biotech services firm developing and manufacturing biologics, including AAV viral vectors for gene therapies.
Paragon Bioservices, Inc. provides biologics development and manufacturing services, with a focus on gene therapies and viral vectors such as adeno-associated virus (AAV) vectors. Founded in 1990 in Baltimore, US, it operates as a subsidiary of Catalent, Inc., which acquired it for USD 1.2 billion in a deal finalized in May 2019. The company has completed five deals, with its latest funding round in April 2019, and it is at Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in